# Elizabeth E Powell

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 151 papers | 11,115 citations | 47 h-index | 104 g-index |
| 165 ext. papers | 12,817 ext. citations | 6.5 avg, IF | 5.82 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 151 | IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nature Genetics*, **2009**, 41, 1100-4 | 36.3 | 1636 |
| 150 | The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. *Hepatology*, **1990**, 11, 74-80 | 11.2 | 1172 |
| 149 | Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology*, **1999**, 29, 1215-9 | 11.2 | 559 |
| 148 | Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology*, **2006**, 130, 1636-42 | 13.3 | 449 |
| 147 | Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. *Gastroenterology*, **2007**, 133, 80-90 | 13.3 | 363 |
| 146 | Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. *Hepatology*, **1999**, 30, 526-30 | 11.2 | 354 |
| 145 | Host genetic factors influence disease progression in chronic hepatitis C. *Hepatology*, **2000**, 31, 828-33 | 11.2 | 340 |
| 144 | Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. *Gut*, **2004**, 53, 413-9 | 19.2 | 310 |
| 143 | Steatosis: co-factor in other liver diseases. *Hepatology*, **2005**, 42, 5-13 | 11.2 | 290 |
| 142 | Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. *Hepatology*, **2005**, 41, 809-18 | 11.2 | 284 |
| 141 | Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. *Gastroenterology*, **2001**, 121, 148-55 | 13.3 | 244 |
| 140 | The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. *Hepatology*, **2014**, 59, 1393-405 | 11.2 | 235 |
| 139 | Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. *Gut*, **2006**, 55, 529-35 | 19.2 | 216 |
| 138 | Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. *Gut*, **2002**, 51, 89-94 | 19.2 | 204 |
| 137 | Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. *Journal of Magnetic Resonance Imaging*, **2008**, 28, 937-45 | 5.6 | 149 |
| 136 | In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. *Journal of Hepatology*, **2003**, 39, 1042-8 | 13.4 | 145 |
| 135 | Non-alcoholic fatty liver disease. *Lancet, The*, **2021**, 397, 2212-2224 | 40 | 145 |

| | | | |
|---|---|---|---|
| 134 | Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. *Gastroenterology*, **2017**, 152, 1078-1089 | 13.3 | 137 |
| 133 | Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. *Journal of Hepatology*, **2009**, 51, 389-97 | 13.4 | 133 |
| 132 | Steatosis is a cofactor in liver injury in hemochromatosis. *Gastroenterology*, **2005**, 129, 1937-43 | 13.3 | 129 |
| 131 | Interferon- rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. *Nature Communications*, **2015**, 6, 6422 | 17.4 | 127 |
| 130 | Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. *Hepatology*, **2004**, 39, 1230-8 | 11.2 | 120 |
| 129 | Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. *Journal of Hepatology*, **2001**, 34, 314-20 | 13.4 | 120 |
| 128 | GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. *Endocrinology*, **2011**, 152, 181-92 | 4.8 | 118 |
| 127 | Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology*, **2012**, 143, 1244-1252.e12 | 13.3 | 111 |
| 126 | Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. *International Journal of Epidemiology*, **2003**, 32, 717-24 | 7.8 | 110 |
| 125 | IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. *PLoS Medicine*, **2011**, 8, e1001092 | 11.6 | 93 |
| 124 | Adiponectin and its receptors in patients with chronic hepatitis C. *Journal of Hepatology*, **2005**, 43, 929-36 | 13.4 | 86 |
| 123 | Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. *Journal of Hepatology*, **2003**, 39, 967-71 | 13.4 | 77 |
| 122 | Improvement in chronic hepatocerebral degeneration following liver transplantation. *Gastroenterology*, **1990**, 98, 1079-82 | 13.3 | 77 |
| 121 | MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. *Nature Communications*, **2016**, 7, 12757 | 17.4 | 73 |
| 120 | IFN-, not IFN-, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. *Nature Genetics*, **2017**, 49, 795-800 | 36.3 | 72 |
| 119 | Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver. *Journal of Clinical Investigation*, **1994**, 93, 2168-74 | 15.9 | 72 |
| 118 | Detection of male DNA in the liver of female patients with primary biliary cirrhosis. *Journal of Hepatology*, **2000**, 33, 690-5 | 13.4 | 70 |
| 117 | Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. *Hepatology*, **2016**, 64, 34-46 | 11.2 | 65 |

| | | | |
|---|---|---|---|
| 116 | Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. *Hepatology*, **2011**, 53, 1819-29 | 11.2 | 64 |
| 115 | Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. *Journal of Gastroenterology and Hepatology (Australia)*, **2003**, 18, 386-92 | 4 | 62 |
| 114 | Steatohepatitis associated with limb lipodystrophy. *Gastroenterology*, **1989**, 97, 1022-4 | 13.3 | 61 |
| 113 | Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. *Hepatology*, **2008**, 48, 80-7 | 11.2 | 60 |
| 112 | Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. *Frontiers in Immunology*, **2019** , 10, 293 | 8.4 | 59 |
| 111 | Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. *Genome Medicine*, **2011**, 3, 57 | 14.4 | 57 |
| 110 | FibroGENE: A gene-based model for staging liver fibrosis. *Journal of Hepatology*, **2016**, 64, 390-398 | 13.4 | 55 |
| 109 | Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. *Internal Medicine Journal*, **2018**, 48, 144-151 | 1.6 | 53 |
| 108 | CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. *Genes and Immunity*, **2004**, 5, 444-50 | 4.4 | 51 |
| 107 | Peripheral blood chimerism following human liver transplantation. *Hepatology*, **1997**, 25, 1233-6 | 11.2 | 50 |
| 106 | Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: An aid to diagnosis. *Hepatology*, **1991**, 13, 455-459 | 11.2 | 48 |
| 105 | Can paracetamol (acetaminophen) be administered to patients with liver impairment?. *British Journal of Clinical Pharmacology*, **2016**, 81, 210-22 | 3.8 | 48 |
| 104 | Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. *Internal Medicine Journal*, **2013**, 43, 247-53 | 1.6 | 45 |
| 103 | ELF score 9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. *Liver International*, **2015**, 35, 1673-81 | 7.9 | 43 |
| 102 | Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis. *Science Translational Medicine*, **2019**, 11, | 17.5 | 42 |
| 101 | Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. *BMJ Open*, **2015**, 5, e007451 | 3 | 42 |
| 100 | Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. *Journal of Hepatology*, **2008**, 49, 1046-54 | 13.4 | 41 |
| 99 | Interaction of non-alcoholic fatty liver disease with other liver diseases. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2002**, 16, 767-81 | 2.5 | 41 |

| | | | |
|---|---|---|---|
| 98 | Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. *Liver International*, **2013**, 33, 624-32 | 7.9 | 40 |
| 97 | A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. *Journal of Medical Genetics*, **2005**, 42, e45 | 5.8 | 38 |
| 96 | Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration. *World Journal of Gastroenterology*, **2014**, 20, 17851-62 | 5.6 | 37 |
| 95 | Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. *Digestive Diseases*, **2010**, 28, 186-91 | 3.2 | 36 |
| 94 | Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C. *Liver International*, **2013**, 33, 569-79 | 7.9 | 35 |
| 93 | Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change?. *Internal Medicine Journal*, **2014**, 44, 865-72 | 1.6 | 35 |
| 92 | Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. *Clinics in Liver Disease*, **2007**, 11, 173-89, x | 4.6 | 34 |
| 91 | Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. *Journal of Gastroenterology and Hepatology (Australia)*, **1999**, 14, 419-22 | 4 | 34 |
| 90 | Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. *Psychosomatics*, **2004**, 45, 49-57 | 2.6 | 33 |
| 89 | The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. *Liver International*, **2016**, 36, 370-7 | 7.9 | 32 |
| 88 | CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites. *JCI Insight*, **2016**, 1, e86914 | 9.9 | 32 |
| 87 | A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. *Hepatology Communications*, **2018**, 2, 893-905 | 6 | 32 |
| 86 | Virus-specific CD8+ T lymphocytes within the normal human liver. *European Journal of Immunology*, **2004**, 34, 1526-31 | 6.1 | 29 |
| 85 | Macrophage secretory products induce an inflammatory phenotype in hepatocytes. *World Journal of Gastroenterology*, **2012**, 18, 1732-44 | 5.6 | 29 |
| 84 | Role of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation. *Liver Transplantation*, **2001**, 7, 255-63 | 4.5 | 28 |
| 83 | The toll-like receptor 3 pathway in homeostasis, responses to injury and wound repair. *Seminars in Cell and Developmental Biology*, **2017**, 61, 22-30 | 7.5 | 27 |
| 82 | Nonalcoholic fatty liver disease: is all the fat bad?. *Internal Medicine Journal*, **2004**, 34, 187-91 | 1.6 | 27 |
| 81 | Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection. *PLoS ONE*, **2015**, 10, e0120642 | 3.7 | 25 |

| | | | |
|---|---|---|---|
| 80 | Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. *BMC Gastroenterology* , **2014**, 14, 97 | 3 | 24 |
| 79 | Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management. *Medicine (United States)*, **2017**, 96, e6761 | 1.8 | 23 |
| 78 | Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy. *Journal of Gastroenterology and Hepatology (Australia)*, **1999**, 14, 801-3 | 4 | 23 |
| 77 | Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation. *PLoS ONE*, **2016**, 11, e0157771 | 3.7 | 23 |
| 76 | Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury. *Fibrogenesis and Tissue Repair*, **2015**, 8, 19 | | 22 |
| 75 | Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers. *PLoS ONE*, **2016**, 11, e0167001 | 3.7 | 22 |
| 74 | Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. *JCI Insight*, **2018**, 3, | 9.9 | 21 |
| 73 | Nonalcoholic fatty liver disease burden: Australia, 2019-2030. *Journal of Gastroenterology and Hepatology (Australia)*, **2020**, 35, 1628-1635 | 4 | 21 |
| 72 | Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention. *Hepatology Communications*, **2019**, 3, 620-631 | 6 | 20 |
| 71 | Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. *BMC Gastroenterology*, **2016**, 16, 114 | 3 | 20 |
| 70 | Obesity management in liver clinics: translation of research into clinical practice. *Journal of Gastroenterology and Hepatology (Australia)*, **2007**, 22, 504-9 | 4 | 20 |
| 69 | Increasing Hospitalization Rates for Cirrhosis: Overrepresentation of Disadvantaged Australians. *EClinicalMedicine*, **2019**, 11, 44-53 | 11.3 | 18 |
| 68 | Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. *Metabolism: Clinical and Experimental*, **2018**, 78, 80-94 | 12.7 | 18 |
| 67 | Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model. *American Journal of Pathology*, **2016**, 186, 524-38 | 5.8 | 18 |
| 66 | Chronic hepatitis C and steatosis. *Current Hepatitis Reports*, **2004**, 3, 123-128 | | 18 |
| 65 | Haemochromatosis: a clinical update for the practising physician. *Internal Medicine Journal*, **2018**, 48, 509-516 | 1.6 | 17 |
| 64 | Expression of cytokines and factors modulating apoptosis by human sinusoidal leucocytes. *Journal of Hepatology*, **2000**, 32, 392-8 | 13.4 | 16 |
| 63 | Detection of circulating donor deoxyribonucleic acid by microsatellite analysis in a liver transplant recipient. *Liver Transplantation*, **1996**, 2, 391-4 | | 15 |

| | | | |
|---|---|---|---|
| 62 | Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. *World Journal of Gastroenterology*, **2017**, 23, 7321-7331 | 5.6 | 15 |
| 61 | Optimising care of patients with chronic disease: patient-oriented education may improve disease knowledge and self-management. *Internal Medicine Journal*, **2017**, 47, 952-955 | 1.6 | 14 |
| 60 | No evidence of the unfolded protein response in patients with chronic hepatitis C virus infection. *Journal of Gastroenterology and Hepatology (Australia)*, **2011**, 26, 319-27 | 4 | 14 |
| 59 | Lymphocyte apoptosis and cell replacement in human liver allografts. *Transplantation*, **2002**, 73, 1828-34 | 1.8 | 14 |
| 58 | Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia. *Internal Medicine Journal*, **2017**, 47, 429-435 | 1.6 | 13 |
| 57 | Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammation. *British Journal of Pharmacology*, **2019**, 176, 3775-3790 | 8.6 | 13 |
| 56 | Serum soluble CD23 but not IL8, IL10, GM-CSF, or IFN-gamma is elevated in patients with hepatitis C infection. *Clinical Immunology and Immunopathology*, **1997**, 84, 139-44 | | 13 |
| 55 | Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. *Molecular Diagnosis and Therapy*, **2008**, 12, 209-18 | 4.5 | 12 |
| 54 | Use of standardised assessment forms in referrals to hepatology outpatient services: implications for accurate triaging of patients with chronic hepatitis C. *Australian Health Review*, **2013**, 37, 218-22 | 1.8 | 11 |
| 53 | Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. *Trials*, **2017**, 18, 339 | 2.8 | 10 |
| 52 | Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease. *Canadian Journal of Gastroenterology and Hepatology*, **2017**, 2017, 7927685 | 2.8 | 10 |
| 51 | Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC). *Patient Preference and Adherence*, **2020**, 14, 599-611 | 2.4 | 10 |
| 50 | Khat-associated hepatitis. *Medical Journal of Australia*, **2013**, 199, 498-9 | 4 | 9 |
| 49 | Successful in vitro fertilization and pregnancy in a patient with autoimmune chronic active hepatitis and cirrhosis. *Journal of Gastroenterology and Hepatology (Australia)*, **1995**, 10, 233-5 | 4 | 9 |
| 48 | Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: An aid to diagnosis **1991**, 13, 455 | | 9 |
| 47 | Liver, lipoproteins and disease: I. Biochemistry of lipoprotein metabolism. *Journal of Gastroenterology and Hepatology (Australia)*, **1992**, 7, 214-24 | 4 | 8 |
| 46 | Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. *Journal of Gastroenterology and Hepatology (Australia)*, **2021**, 36, 873-884 | 4 | 8 |
| 45 | Assessment of alcohol histories obtained from patients with liver disease: opportunities to improve early intervention. *Internal Medicine Journal*, **2013**, 43, 1096-102 | 1.6 | 7 |

| | | | |
|---|---|---|---|
| 44 | ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies. *BMJ Open Gastroenterology*, **2020**, 7, | 3.9 | 7 |
| 43 | Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease. *Internal Medicine Journal*, **2016**, 46, 420-6 | 1.6 | 7 |
| 42 | A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-1 dependent mechanisms. *Scientific Reports*, **2019**, 9, 1439 | 4.9 | 6 |
| 41 | Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics. *Hepatology Communications*, **2020**, 4, 518-526 | 6 | 6 |
| 40 | BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin. *Alcoholism: Clinical and Experimental Research*, **2013**, 37, 1771-8 | 3.7 | 6 |
| 39 | Role of donor leukocyte chimerism in establishing the etiology of neutropenia after liver transplantation. *Transplantation*, **1999**, 67, 1358-61 | 1.8 | 6 |
| 38 | Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis. *Hepatology Communications*, **2020**, 4, 1279-1292 | 6 | 6 |
| 37 | Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 68-77 | 6.1 | 6 |
| 36 | Hospitalisation for cirrhosis in Australia: disparities in presentation and outcomes for Indigenous Australians. *International Journal for Equity in Health*, **2020**, 19, 27 | 4.6 | 5 |
| 35 | CCR5-32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. *Genes and Immunity*, **2013**, 14, 286-90 | 4.4 | 5 |
| 34 | Liver, lipoproteins and disease: II. Clinical relevance of disordered cholesterol metabolism in liver disease. *Journal of Gastroenterology and Hepatology (Australia)*, **1992**, 7, 225-31 | 4 | 5 |
| 33 | Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.. *Journal of Hepatology*, **2022**, | 13.4 | 5 |
| 32 | Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. *Journal of Diabetes and Its Complications*, **2018**, 32, 799-804 | 3.2 | 5 |
| 31 | Increased mononuclear cell activation and apoptosis early after human liver transplantation is associated with a reduced frequency of acute rejection. *Liver Transplantation*, **2004**, 10, 397-403 | 4.5 | 4 |
| 30 | Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis. *Internal Medicine Journal*, **2021**, 51, 691-698 | 1.6 | 4 |
| 29 | Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. *BMJ Open Gastroenterology*, **2021**, 8, | 3.9 | 4 |
| 28 | Contemporary Educational Interventions for General Practitioners (GPs) in Primary Care Settings in Australia: A Systematic Literature Review. *Frontiers in Public Health*, **2019**, 7, 176 | 6 | 3 |
| 27 | Kupffer cells and hepatocyte metabolism: a two-way street?. *Hepatology*, **2009**, 49, 690-2 | 11.2 | 3 |

| | | | |
|---|---|---|---|
| 26 | Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. *Scientific Reports*, **2021**, 11, 2858 | 4.9 | 3 |
| 25 | Identifying areas of need relative to liver disease: geographic clustering within a health service district. *Australian Health Review*, **2017**, 41, 407-418 | 1.8 | 2 |
| 24 | Engaging primary care clinicians in the assessment of NAFLD. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 458-460 | 24.2 | 2 |
| 23 | Weight-based tacrolimus trough concentrations post liver transplant. *Internal Medicine Journal*, **2019**, 49, 79-83 | 1.6 | 2 |
| 22 | Liver repercussions of defective gut surveillance. *Hepatology*, **2012**, 56, 1174-7 | 11.2 | 2 |
| 21 | Triage of referrals to outpatient hepatology services: an ineffective tool to prioritise patients?. *Australian Health Review*, **2012**, 36, 443-7 | 1.8 | 2 |
| 20 | Intensive dietary intervention improves weight maintenance in the management of non-alcoholic fatty liver disease. *Journal of Hepatology*, **2002**, 36, 256 | 13.4 | 2 |
| 19 | An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care.. *Diabetic Medicine*, **2022**, e14799 | 3.5 | 2 |
| 18 | Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis. *Internal Medicine Journal*, **2020**, 50, 1142-1146 | 1.6 | 2 |
| 17 | Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia. *EClinicalMedicine*, **2021**, 36, 100919 | 11.3 | 2 |
| 16 | Not every cell is as it seems: a role for ductular epithelial cells in fibrosis?. *Gut*, **2011**, 60, 1-2 | 19.2 | 1 |
| 15 | Combined approach for non-invasive measurement of liver pathology by MR. *Journal of Hepatology*, **2009**, 51, 1083-1084 | 13.4 | 1 |
| 14 | Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCal assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD). *BMC Health Services Research*, **2020**, 20, 335 | 2.9 | 1 |
| 13 | The Patient‐Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age. *Hepatology Communications*, **2021**, 5, 891-905 | 6 | 1 |
| 12 | Disruption of the circadian clock component BMAL1 elicits an endocrine adaption impacting on insulin sensitivity and liver disease.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2200083119 | 11.5 | 1 |
| 11 | Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study. *BMJ Open Gastroenterology*, **2021**, 8, | 3.9 | 1 |
| 10 | Disparities in Unmet Needs in Indigenous and Non-Indigenous Australians with Cirrhosis: An Exploratory Study. *Patient Preference and Adherence*, **2021**, 15, 2649-2658 | 2.4 | 0 |
| 9 | The temporal pattern and lifestyle associations of respiratory virus infection in a cohort study spanning the first two years of life.. *BMC Pediatrics*, **2022**, 22, 166 | 2.6 | 0 |

| | | | |
|---|---|---|---|
| 8 | Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.. *BMC Health Services Research*, **2022**, 22, 487 | 2.9 | 0 |
| 7 | The Impact of Social Workers in Cirrhosis Care: a Systematic Review. *Current Treatment Options in Gastroenterology*,1 | 2.5 | 0 |
| 6 | Patient-oriented medication education intervention has long-term benefits for people with decompensated cirrhosis.. *Hepatology Communications*, **2022**, | 6 | 0 |
| 5 | Epidemiology of ascites fluid infections in patients with cirrhosis in Queensland, Australia from 2008 to 2017. *Medicine (United States)*, **2022**, 101, e29217 | 1.8 | 0 |
| 4 | Reply. *Hepatology Communications*, **2019**, 3, 1283-1284 | 6 | |
| 3 | New Paradigms in the Histopathology of NAFLD. *Current Hepatology Reports*, **2014**, 13, 81-87 | 1 | |
| 2 | Response to ELF cut-off points: aetiology is also a relevant factor. *Liver International*, **2015**, 35, 1921 | 7.9 | |
| 1 | Does NASH or NAFLD Contribute to Comorbidity of Other Liver Diseases?276-288 | | |